Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Embracing and Releasing the Power of Data

Posted on May 24th, 2016 by

Pharma R&D


Big data have huge potential in pharmaceutical research, especially now that the technology to manage, mine and assess the vast amount of available information is catching up with the reality of researchers’ needs. Where it once would have taken many months to effectively trawl Continue reading “Embracing and Releasing the Power of Data” »

Practical aspects of the “new” IND Rule

Posted on May 23rd, 2016 by



The FDA IND reporting rule[i], mandatory since March 2011, has had a major impact on the sponsor’s responsibilities to report safety information representing a potential change in the risk profile for products that are under investigation. Continue reading “Practical aspects of the “new” IND Rule” »

Biosimilars and Pharmacovigilance: What’s Ahead

Posted on May 20th, 2016 by


DNA Magnification

DNA Magnification

In our first blog in this series, we drew from a recent IMS report  to demonstrate the market potential of biosimilars. Continue reading “Biosimilars and Pharmacovigilance: What’s Ahead” »

Molecular Relatives: Prodrugs

Posted on May 19th, 2016 by

Pharma R&D


I’m an avid sailor, and on our boat we have an amazing device known as a water-maker. It is probably one of the most useful pieces of equipment on board for long cruises, as it takes in sea water, and, through a process of reverse osmosis, provides potable drinking water. Continue reading “Molecular Relatives: Prodrugs” »

Can a mosquito change the world?

Posted on May 18th, 2016 by



It is night, you are trying to sleep and you hear a mosquito in your bedroom. Can you sleep? Continue reading “Can a mosquito change the world?” »

The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions

Posted on May 6th, 2016 by



After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail.  Continue reading “The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions” »

  1. 1
  2. …
  3. 43
  4. 44
  5. 45
  6. 46
  7. 47
  8. …
  9. 55

About this Blog


The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.